SRDX News and Press, Surmodics Inc. From 01/19/23

Surmodics’ proprietary Crystalline Drug Release (CDR) platform enhances sirolimus stability, transfer, and retention in tissue CDR discussed in connection with 12-month data from Surmodics’ SWING trial of the Sundance™ Sirolimus-Coated Balloon Surmodics, Inc. (N...

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received a letter from the U.S. Food and Drug Administration (FDA; the Agency) related to its premarket approval (PMA) application for the S...

Summary Inotiv's recently acquired companies cause its revenue to spike tremendously. However, the company's expenses are just as great, and not all of the largest cost items are one-time costs, meaning the company could remain unprofitable for a long time. Specifically, the Goodwil...

35-subject SWING Trial evaluates the safety, performance of Surmodics’ Sundance™ Sirolimus Drug-Coated Balloon Differentiated capabilities of Surmodics’ crystalline drug release platform to be discussed in connection with SWING trial 12-month data Surmodics,...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Sundance™ Sirolimus Drug-Coated Balloon exhibits excellent safety profile Primary patency maintained at 12 months in 80% of per protocol analysis population Surmodics, Inc. (NASDAQ:SRDX) (the “Company”), a leading provider of medical device and i...

Surmodics, Inc. (SRDX) Q4 2022 Earnings Conference Call November 09, 2022, 10:00 ET Company Participants Gary Maharaj - CEO, President & Director Timothy Arens - SVP, Finance & Information Technology & CFO Conference Call Participants Michael ...

The following slide deck was published by Surmodics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Surmodics, Inc. 2022 Q4 - Results - Earnings Call Presentation

35-subject SWING Trial evaluates the safety, efficacy of Surmodics’ Sundance™ Sirolimus Drug-Coated Balloon Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today...